Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 4/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25074171 | 0.72 | MAPK1 (0.49) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL2019231 | 0.68 | MAPK1 (0.53) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL253558 | 0.67 | P2RX7 (0.46) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL19885229 | 0.66 | LPL (0.39) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL25217559 | 0.65 | P2RX7 (0.44) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL2315023 | 0.64 | P2RX7 (0.52) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL15465801 | 0.63 | P2RX7 (0.46) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL17646898 | 0.62 | P2RX7 (0.37) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL1586037 | 0.62 | MAPK1 (0.67) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL12375671 | 0.62 | P2RX7 (0.41) | MAPK1P2RX7LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | MAPK1 931/4885P2RX7 4684/4885LPL 4560/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | MAPK1 788/4885P2RX7 4465/4885LPL 4681/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | MAPK1 788/4885P2RX7 4465/4885LPL 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.